Research ArticleCardiovascular
Inhibition of Factor XIa Reduces the Frequency of Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in Rabbits
Xinkang Wang, Stan Kurowski, Weizhen Wu, Gino A. Castriota, Xueping Zhou, Lin Chu, Kenneth P. Ellsworth, Donald Chu, Scott Edmondson, Amjad Ali, Patrick Andre, Dietmar Seiffert, Mark Erion, David E. Gutstein and Zhu Chen
Journal of Pharmacology and Experimental Therapeutics March 2017, 360 (3) 476-483; DOI: https://doi.org/10.1124/jpet.116.238600
Xinkang Wang
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Stan Kurowski
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Weizhen Wu
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Gino A. Castriota
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Xueping Zhou
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Lin Chu
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Kenneth P. Ellsworth
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Donald Chu
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Scott Edmondson
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Amjad Ali
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Patrick Andre
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Dietmar Seiffert
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Mark Erion
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
David E. Gutstein
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Zhu Chen
Cardiometabolic Disease Biology (X.W., S.K., W.W., G.A.C., X.Z., P.A., D.S., M.E., D.E.G., Z.C.), Discovery Pharmaceutical Sciences (L.C.), In Vitro Pharmacology (K.E., D.C.), and Discovery Chemistry (S.E.), Merck Research Laboratories, Kenilworth, New Jersey; Lead Optimization Chemistry, Merck Research Laboratories, Rahway, New Jersey (A.A.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleCardiovascular
FXIa Inhibitor Reduces Cerebral Microembolic Signals
Xinkang Wang, Stan Kurowski, Weizhen Wu, Gino A. Castriota, Xueping Zhou, Lin Chu, Kenneth P. Ellsworth, Donald Chu, Scott Edmondson, Amjad Ali, Patrick Andre, Dietmar Seiffert, Mark Erion, David E. Gutstein and Zhu Chen
Journal of Pharmacology and Experimental Therapeutics March 1, 2017, 360 (3) 476-483; DOI: https://doi.org/10.1124/jpet.116.238600
Research ArticleCardiovascular
FXIa Inhibitor Reduces Cerebral Microembolic Signals
Xinkang Wang, Stan Kurowski, Weizhen Wu, Gino A. Castriota, Xueping Zhou, Lin Chu, Kenneth P. Ellsworth, Donald Chu, Scott Edmondson, Amjad Ali, Patrick Andre, Dietmar Seiffert, Mark Erion, David E. Gutstein and Zhu Chen
Journal of Pharmacology and Experimental Therapeutics March 1, 2017, 360 (3) 476-483; DOI: https://doi.org/10.1124/jpet.116.238600
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement